Advanced in Osteosarcoma

Dr. Jeffrey S. Dome

Pediatric Hematology Oncology

111 Michigan Ave Nw, Children's National Medical Center,

Washington, DC

Clinical Trials:Currently Recruiting for 1 Trial

Advanced in Osteosarcoma

111 Michigan Ave Nw, Children's National Medical Center,

Washington, DC

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Dome is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Dome is rated as an Advanced provider by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Rhabdoid Tumor, Denys-Drash Syndrome (DDS), Neuroblastoma, Nephrectomy, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 114 peer reviewed articles and participating in 79 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 18 clinical trials in the study of Osteosarcoma.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in DC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Cigna

Humana

HMO
INDEMNITY
POS
PPO

Locations

111 Michigan Ave Nw, Children's National Medical Center, Washington, DC 20010

Call: 202-476-2800

Additional Areas of Focus

Dr. Dome has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

79 Clinical Trials

Multi-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

Enrollment Status: Recruiting

Publish Date: May 31, 2025

Intervention Type: Biological

Study Drug: Tumor Associated Antigen Lymphocytes (TAA-T)

Study Phase: Phase 1

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: October 15, 2025

Intervention Type: Drug, Biological, Procedure, Other, Radiation

Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine

Study Phase: Phase 3

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Enrollment Status: Active_not_recruiting

Publish Date: October 15, 2025

Intervention Type: Drug, Procedure, Biological, Other, Radiation

Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Enrollment Status: Active_not_recruiting

Publish Date: October 10, 2025

Intervention Type: Drug, Biological

Study Drugs: Axitinib, Nivolumab

Study Phase: Phase 2

A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Drug, Biological, Procedure, Radiation

Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine

Study Phase: Phase 2

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Drug, Radiation

Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Drug, Procedure, Biological, Radiation

Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

Enrollment Status: Active_not_recruiting

Publish Date: October 06, 2025

Intervention Type: Procedure, Other, Biological

Study Drugs: Lactobacillus Plantarum Strain 299, Lactobacillus Plantarum Strain 299v

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Other, Drug

Study Drug: Ulixertinib

Study Phase: Phase 2

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: September 23, 2025

Intervention Type: Biological, Drug, Procedure, Radiation

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate

Study Phase: Phase 3

A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Brentuximab, Ipilimumab, Nivolumab

Study Phase: Phase 1/Phase 2

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Radiation, Drug, Biological, Other

Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine

Study Phase: Phase 3

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure

A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Behavioral, Other, Procedure

Study Drug: 6-Mercaptopurine

Study Phase: Phase 3

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Radiation

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Erdafitinib

Study Phase: Phase 2

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Procedure, Other, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Procedure, Radiation, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Other, Procedure

StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors

Enrollment Status: Active_not_recruiting

Publish Date: September 04, 2025

Intervention Type: Other, Behavioral, Device

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Enrollment Status: Active_not_recruiting

Publish Date: September 02, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate

Study Phase: Phase 3

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Enrollment Status: Active_not_recruiting

Publish Date: August 21, 2025

Intervention Type: Drug, Other, Radiation

Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: August 21, 2025

Intervention Type: Drug, Biological, Radiation

Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Tyrosine Kinase Inhibitor

Study Phase: Phase 2

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide

Study Phase: Phase 3

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2025

Intervention Type: Drug, Radiation, Procedure

Study Drugs: Doxorubicin, Ifosfamide, Pazopanib

Study Phase: Phase 2/Phase 3

A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2025

Intervention Type: Other, Drug

Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib

Study Phase: Phase 3

Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate

Study Phase: Phase 3

A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: August 03, 2025

Intervention Type: Drug

Study Drugs: Onivyde, Talazoparib, Temozolomide

Study Phase: Phase 1/Phase 2

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Enrollment Status: Active_not_recruiting

Publish Date: August 01, 2025

Intervention Type: Drug, Other

Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Tipifarnib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Ivosidenib

Study Phase: Phase 2

A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Procedure, Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Nirogacestat

Study Phase: Phase 2

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Drug, Biological

Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: July 09, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Enrollment Status: Completed

Publish Date: April 23, 2025

Intervention Type: Other, Drug

Study Drug: Carvedilol

Study Phase: Phase 2

A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents With Cancer

Enrollment Status: Active_not_recruiting

Publish Date: April 18, 2025

Intervention Type: Other, Device

Study Phase: Phase 3

Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study

Enrollment Status: Active_not_recruiting

Publish Date: April 10, 2025

Intervention Type: Other, Procedure

Study Phase: Not Applicable

Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: April 01, 2025

Intervention Type: Other, Drug

Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

Renal Tumors Classification, Biology, and Banking Study

Enrollment Status: Active_not_recruiting

Publish Date: March 25, 2025

Intervention Type: Other

A Phase 1 Study of Palbociclib (IND#141416), A CDK 4/6 Inhibitor, in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Enrollment Status: Completed

Publish Date: March 21, 2025

Intervention Type: Drug

Study Drugs: Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone

Study Phase: Phase 1

Key Adverse Events After Childhood Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 07, 2025

Intervention Type: Other

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement

Enrollment Status: Completed

Publish Date: February 27, 2025

Intervention Type: Procedure, Drug

Study Drugs: Azacitidine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Hydrocortisone, Leucovorin, Mercaptopurine, Methotrexate, PEG-Asparaginase, Prednisolone, Thioguanine, Vincristine

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Completed

Publish Date: February 05, 2025

Intervention Type: Drug, Other

Study Drugs: Selumetinib, Selumetinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Procedure, Drug

Study Drug: Samotolisib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Drug: Vemurafenib

Study Phase: Phase 2

View 49 Less Clinical Trials

114 Total Publications

Updated favourable-histology Wilms tumour risk stratification: rationale for future Children's Oncology Group clinical trials.

Journal: Nature reviews. Urology

Published: May 30, 2025

View All 114 Publications

Similar Doctors

Elite in Osteosarcoma

Dr. Jeffrey A. Toretsky

Pediatric Hematology Oncology

Elite in Osteosarcoma

Dr. Jeffrey A. Toretsky

Pediatric Hematology Oncology

3800 Reservoir Rd Nw,

Washington, DC

(3.4 miles away)

202-444-7599

Languages Spoken:

English

See accepted insurances

Jeffrey Toretsky is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Toretsky is rated as a Distinguished provider by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration.

Elite in Osteosarcoma

Dr. Paul S. Meltzer

Pediatric Hematology Oncology

Elite in Osteosarcoma

Dr. Paul S. Meltzer

Pediatric Hematology Oncology

10 Center Dr,

Bethesda, MD

(7.1 miles away)

301-318-2421

Languages Spoken:

English

Paul Meltzer is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Meltzer is rated as a Distinguished provider by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Rhabdomyosarcoma, and Pancreaticoduodenectomy.

Distinguished in Osteosarcoma

Dr. Sharon A. Savage

Pediatric Hematology Oncology

Distinguished in Osteosarcoma

Dr. Sharon A. Savage

Pediatric Hematology Oncology

10 Center Drive, National Institutes Of Health Clinical Center,

Bethesda, MD

(7.1 miles away)

240-276-7241

Languages Spoken:

English

Sharon Savage is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Savage is rated as an Elite provider by MediFind in the treatment of Osteosarcoma. Her top areas of expertise are Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

VIEW MORE OSTEOSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dome's expertise for a condition

ConditionClose